Corey Cutler
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Corey Cutler as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05922761 · BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)Dana-Farber Cancer Institute · recruiting · Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases · principal investigator
- Ph2NCT02867384 · Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell TransplantationDana-Farber Cancer Institute · completed · Graft vs. Host Disease · principal investigator
- Ph2NCT02176031 · Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHDDana-Farber Cancer Institute · completed · Graft Versus Host Disease · principal investigator
- Ph2NCT01226420 · Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host DiseaseDana-Farber Cancer Institute · terminated · Chronic Graft-versus-host Disease · principal investigator
- Ph1NCT00890500 · Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.Fate Therapeutics · completed · Hematologic Malignancies, Allogeneic Stem Cell Transplantation · principal investigator
- Ph2NCT00548717 · Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute · terminated · Graft-vs-Host Disease · principal investigator
- Ph1NCT00495755 · Campath in Chronic GVHDDana-Farber Cancer Institute · completed · Chronic Graft-vs.-Host Disease · study chair
- Ph1/Ph2NCT00379587 · Rituximab for Prevention of Chronic GVHDDana-Farber Cancer Institute · completed · Hematological Malignancies · principal investigator
- Ph2NCT00144703 · Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationDana-Farber Cancer Institute · completed · Hematologic Malignancies, Myelogenous Leukemia, Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT00144677 · Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationDana-Farber Cancer Institute · completed · Acute Myelogenous Leukemia, Graft Versus Host Disease, Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Admin CoreP01HL158505 · NHLBI · DANA-FARBER CANCER INST · fiscal years 2022 to 2026 · $45,430 awarded in 2026Same name and institution; not confirmed by an ID
- Core A: Administrative CoreP01CA142106 · NCI · DANA-FARBER CANCER INST · fiscal years 2015 to 2019 · $125,955 awarded in 2019Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:34 UTC. The ranking covers the 200 most relevant of 111 PubMed records, and a shared surname and initials can bring in a namesake. All 111 on PubMed
- Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies.Gastroenterology · 19971,292 citationsRCR 39.4
- Interleukin-2 and regulatory T cells in graft-versus-host disease.N Engl J Med · 2011937 citationsRCR 22.1
- Peripheral-blood stem cells versus bone marrow from unrelated donors.N Engl J Med · 2012731 citationsRCR 21.3
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation.N Engl J Med · 2016514 citationsRCR 15.5
- 460 citationsRCR 12.9
- 420 citationsRCR 15.0
- Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.Sci Transl Med · 2013407 citationsRCR 10.8
- 350 citationsRCR 8.6
- 313 citationsRCR 19.8
- Double unrelated reduced-intensity umbilical cord blood transplantation in adults.Biol Blood Marrow Transplant · 2007245 citationsRCR 6.0